More than $62.9 million awarded to Monash for vital medical research
34 Monash University research projects have been awarded a combined total of more than $62.9 million in the latest National Health and Medical Research Council (NHMRC) Investigator Grants scheme.
NHMRC Investigator Grants provide the highest-performing researchers at all career stages with consolidated funding, specifically for research across the four pillars of health and medical research: biomedical, clinical, public health and health services research.
To date, the 2023 NHMRC grant application round has resulted in the commitment of more than $908.2 million to fund 686 grants for health and medical research within Australia.
Funding has been awarded across a diverse range of faculties and disciplines, including 29 projects from the Faculties of Medicine, Nursing and Health Sciences, 4 from the Faculty of Pharmacy and Pharmaceutical Sciences and one from the Faculty of Science.
Projects funded include research to improve outcomes for antimicrobial resistance, diabetes in pregnancy, cancer, epilepsy, Hepatitis C and many more.
Projects funded are:
| Prof Patrick Sexton | Structure, function and modulation of peptide hormone G protein-coupled receptors (GPCRs) | $2,953,040.00 |
| Prof Jian Li | Combating antimicrobial resistance: From bedside to bench and therapeutics | $2,953,040.00 |
| Prof Marcus Chen | A new model for improved syphilis management and control | $2,897,165.00 |
| Prof Elizabeth Manias | ENgaginG older people Across transitions of care to improve medication manaGEment (The ENGAGE Project) | $2,897,165.00 |
| Prof Suzanne Nielsen | Transforming approaches to reduce opioid mortality and related harm | $2,897,165.00 |
| Prof Denise Wootten | Mechanistic understanding of biased agonism and dimerisation for co-targeting incretin receptors for metabolic diseases | $2,897,165.00 |
| Prof Benjamin Marsland | Harnessing microbes and metabolites to combat respiratory diseases | $2,897,165.00 |
| Dr Vilija Jokubaitis | What’s pregnancy got to do with it? Prevention of disability in people with Multiple Sclerosis | $2,769,655.00 |
| Assoc Prof Denise O’Connor | Harnessing research translation science to drive ‘the right care’ | $2,769,655.00 |
| Dr Jeremy Barr | Investigating fundamental phage biology to improve the clinical translation of phage therapy | $2,769,655.00 |
| Assoc Prof Paul Lacaze | Genomics applied to public health and prevention | $2,769,655.00 |
| Prof Mariapia Degli-Esposti | Harnessing the immune system to treat viral infections and their complications | $2,753,040.00 |
| Prof Ron Firestein | Targeting the cancer epigenome for therapy | $2,717,732.00 |
| Prof Patrick Kwan | Transforming epilepsy outcomes through innovative technologies | $2,697,165.00 |
| Prof Mark Bellgrove | Neurobiology of decision making in health and disorder | $2,297,165.00 |
| Assoc Prof Karla Hutt | Protecting the ovary from damage to optimise fertility and endocrine health in women | $2,169,655.00 |
| Prof Stuart Hooper | Assisting Infants transition at birth | $1,953,040.00 |
| Mr William Roman | Investigating the transcriptional repair program during muscle reconstruction | $1,586,190.00 |
| Dr Jessica Biesiekierski | Changing the way we use diet in gut disorders: Generating mechanistic knowledge and clinical evidence to inform integrated management | $1,586,190.00 |
| Dr Ian Harding | Hereditary Cerebellar Ataxias: Next-Generation Biomarker Discovery on a Global Scale | $1,586,190.00 |
| Dr Stacey Ellery | Creatine: The Next Frontier in Nutritional Supplements to Reduce Perinatal Brain Injury | $1,586,190.00 |
| Assoc Prof Joseph Doyle | Innovative models of care to eliminate hepatitis C as a public health threat | $1,586,190.00 |
| Dr Gareth Gregory | Improving outcomes for patients with central nervous system lymphoma through precision medicine | $1,293,095.00 |
| Dr Omer Gilan | Understanding and targeting the epigenome in blood cancers | $1,188,491.67 |
| Assoc Prof Daniel Rolnik | Preventing Pre-eclampsia to Improve Outcomes for Mothers and Babies | $793,095.00 |
| Ms Aili Langford | Deprescribing opioid analgesics in primary care to reduce medication-related harm | $662,040.00 |
| Dr Julia Stone | A digital biomarker for circadian medicine: timing is key | $662,040.00 |
| Dr Ram Bhusal | Harnessing ticks’ tricks to develop therapies for inflammatory diseases | $662,040.00 |
| Dr Shobi Sivathamboo | Preventing sudden unexpected death in epilepsy: Discovery of predictive biomarkers and risk factors for precision-based care | $662,040.00 |
| Dr Romain Ragonnet | Designing adaptive strategies to drive tuberculosis towards elimination | $662,040.00 |
| Ms Jane Tiller | Addressing barriers to public trust and participation in genomic medicine | $662,040.00 |
| Dr Adam Shahine | Lipid antigen mediators of T cell responses against Mycobacterium tuberculosis infection | $643,126.69 |
| Dr Arisbel Gondin | Developing safer therapeutic approaches for the treatment of pain via allosteric regulation of opioid receptors | $587,040.00 |
| Dr Rebecca Goldstein | Diabetes and cardiometabolic risk and prevention in pregnancy and beyond | $445,775.29 |